Trastuzumab deruxtecan has shown efficacy in patients ... review of an earlier version of the manuscript; Annie Darilay for design of the trial, development of the trial protocol, statistical ...

She also highlighted a few trial design considerations. Isaacs noted the differing lengths of treatment between arms, with patients on the investigational arm continuing trastuzumab deruxtecan ...

Despite the lack of a study directly comparing trastuzumab deruxtecan and trastuzumab rezetecan ... have a similar type of drug and study design, the same primary endpoint and line of treatment ...

Now that we know what single-agent trastuzumab deruxtecan does in this setting, we can look at biomarkers to develop combination therapies and design randomized phase 2 or phase 3 trials ...

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki improved outcomes compared with capecitabine-based regimens as third-line treatment for certain patients with HER2-positive metastatic breast cancer ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life ...

We hope to add results when they are available. This trial is looking at trastuzumab deruxtecan (T-DXd) with or without pertuzumab for breast cancer that has spread to another part of the body. It is ...